Ligon Discovery
Cambridge · Founded 2007
About Ligon Discovery
Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations.
Company Facts
- Founded: 2007
- Legal name: Ligon Discovery, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.5M
- Funding stage: Seed
- Last round: Seed (Nov 2009)
- Website: ligondiscovery.com
- Phone: 617-453-0952
Social Profiles
Canonical: https://fsome.com/organization/ligon-discovery-8423866 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.